Lymphoma

Lymphoma

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

60 Clinical Trials
Lymphoma NA Active
nct/study# NCT04981795 / MOR208C414

Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant (REAL-MIND)

Learn More
Lymphoma NA Accepting Patients
nct/study# 2020-0081

Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-cell Patients: Real World Experience in Lymphoma Patients

Learn More
Lymphoma NA Accepting Patients
nct/study# 2021-0345

Outcomes and Prognostic Factors of patients diagnosed with high-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study

Learn More
Lymphoma Phase I/II Accepting Patients
nct/study# NCT03331198 / 017004

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Learn More
Lymphoma Phase III Accepting Patients
nct/study# NCT03575351 / JCAR017-BCM-003

A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).

Learn More
Lymphoma N/A Active
nct/study# NCT04982471 / NDS-DLBCL-003

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.